Tirzepatide for Weight Loss
- Non-stimulant – Safe for patients with cardiovascular disease
- Non-addictive, not a controlled substance
- Reduces appetite and food cravings while increasing feeling of fullness
- Lowers weight, waist size, blood pressure, blood sugar, and inflammation
- Majority of patients had at least 15% weight loss at the 5 MG dosage
- Painless, weekly injection into belly fat with a tiny needle
- Newly FDA approved (2022) for Type 2 Diabetes under trademark Mounjaro.
- You are NOT a good candidate for Tirzepatide if you have any of the following: diabetic retinopathy, low blood sugar, decreased kidney function, pancreatitis, gall bladder disease, medullary thyroid cancer (or a family history of medullary thyroid carcinoma), or multiple endocrine neoplasia type 2.
- Potential side effects can include Nausea or vomiting, reflux/heartburn, diarrhea, and stomach pain.
How it works: Tirzepatide for weight loss works by acting on 2 cellular receptors. It mimics 2 peptide hormones; glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that targets areas of the brain that regulate appetite and food intake; it is a powerful appetite suppressant. Tirzepatide has been shown to produce greater reductions of blood sugar and weight as compared to selective GLP-1 receptor agonists like Semaglutide.